63,832 results match your criteria Myeloma


High-risk cytogenetics in multiple myeloma: Further scrutiny of deletions within the IGH gene region enhances risk stratification.

Genes Chromosomes Cancer 2020 May 24. Epub 2020 May 24.

Human Genetics Laboratory, Munroe-Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center, Omaha, Nebraska.

Multiple myeloma is a clonal malignancy of plasma cells in the bone marrow. Risk stratification is partly based on cytogenetic findings that include abnormalities of the IGH locus as determined by fluorescence in situ hybridization (FISH), such as rearrangements that result in either standard-risk or high-risk gene fusions. IGH deletions have been evaluated as a group in multiple myeloma patients with respect to cumulative outcomes but have provided limited guidance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22874DOI Listing

Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma.

Bone Marrow Transplant 2020 May 23. Epub 2020 May 23.

Hematology and Inserm CIC 1402, CHU, Poitiers, France.

Mobilization of peripheral blood stem cells (PBSC) can be performed using plerixafor, which is expensive, or high-dose cyclophosphamide (HDCy). We hypothesized that the overall cost of mobilization with plerixafor might not be greater if the cost of complication management was considered. We performed a cost analysis of these two strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0940-3DOI Listing

Emerging CAR Landscape for Cancer Immunotherapy.

Biochem Pharmacol 2020 May 21:114051. Epub 2020 May 21.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Houston, TX 77030, United States.

In the last decade, there has been great advancement in manipulating the immune system or the cells of the immune system to bring about effective therapies. While harnessing the immune system against cancer is not a new concept, successful reprograming with T cells with chimeric antigen receptor (CAR) forming CAR-T cell therapy has revolutionized the treatment landscape for patients with refractory, high-grade B cell malignancies. The journey from proof-of-concept to FDA-approved commercial CAR-T products has taken almost 3 decades and untold amount of efforts, resources and manpower. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2020.114051DOI Listing

Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date.

Semin Oncol 2020 May 8. Epub 2020 May 8.

Icahn School of Medicine at Mount Sinai, New York City, New York.

Management of multiple myeloma represents an ever changing paradigm with monoclonal antibodies adding the ability to treat patients with 3 and 4 drug regimens with acceptable toxicity profiles. In recent years, we have seen the FDA approve a number of regimens with both elotuzumab and daratumumab in combination with the standard approaches of immunomodulatory drugs, proteasome inhibitors, and steroids. Isatuximab is a naked, humanized IgG1 monoclonal antibody directed against CD38. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2020.04.004DOI Listing

Current concepts and future directions for hemato-oncologic diagnostics.

Crit Rev Oncol Hematol 2020 May 12;151:102977. Epub 2020 May 12.

Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland; Center for Laboratory Medicine (ZLM) and University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address:

At present, hemato-oncologic diagnostics is facing dynamic changes. This applies to the exploration and introduction of novel technologies such as next-generation sequencing or digital droplet PCR for myeloid and lymphatic malignancies in laboratory routine, or liquid biopsy for patients with lymphoid malignancies. Targeted therapies such as FLT3 or IDH1/IDH2 inhibitors for acute myeloid leukemia are entering clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2020.102977DOI Listing

Hematologic malignancy in tanker crewmembers: A case-referent study among male Swedish seafarers.

Am J Ind Med 2020 May 23. Epub 2020 May 23.

Department of Occupational and Environmental Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

Background: Work on Swedish petroleum tankers before the late 1980s has been associated with an increased risk of hematologic malignancy (HM). Since then, ship modernizations have decreased occupational exposure to gases, including the carcinogen benzene. We explored the risk of HMs in Swedish seafarers who had worked on newer types of tankers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajim.23122DOI Listing

Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring.

J Appl Lab Med 2020 Jan;5(1):29-40

Department of Pathology, Division of Clinical Immunopathology, University of Pittsburgh Medical Center, Pittsburgh, PA.

Background: The treatment of multiple myeloma (MM) has been revolutionized by the introduction of therapeutic monoclonal antibodies (tmAbs). Daratumumab, a human IgG1/κ tmAb against CD38 on plasma cells, has improved overall survival in refractory MM and was recently approved as a frontline therapy for MM. Work on tmAb interference with serum protein electrophoresis (SPE) during MM monitoring has failed to provide information for laboratories on incidence of interference and effective methods of managing the interference at a practicable level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/jalm.2019.029009DOI Listing
January 2020

Bortezomib induced purpuric rash.

Dermatol Ther 2020 May 22:e13651. Epub 2020 May 22.

Haematology Department, "Theagenio" Hospital, Thessaloniki, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13651DOI Listing

Society of skeletal radiology member utilization and performance of whole-body MRI in adults.

Skeletal Radiol 2020 May 22. Epub 2020 May 22.

Department of Radiology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Objectives: To evaluate musculoskeletal (MSK) radiologist whole-body magnetic resonance imaging (WBMRI) practice patterns in an effort to better understand current MSK clinical utilization and the need for standardized coding.

Methods: A 12-question survey was created in Survey Monkey®. The survey was e-mailed to Society of Skeletal Radiology (SSR) members on September 19, 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00256-020-03471-3DOI Listing

Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma.

Ann Hematol 2020 May 22. Epub 2020 May 22.

Department of Medicine A, University Hospital Münster, Münster, Germany.

Despite significant progress made in the treatment of patients with multiple myeloma (MM) in the last decade, for patients with early relapse or rapidly progressing high-risk disease, allogeneic hematopoietic stem cell transplantation (SCT) might be an option leading to long-term survival. Here, we retrospectively analyzed the outcomes of 90 MM patients who received allogeneic SCT in our center between 1999 and 2017. We specifically assessed the association of impaired humoral immune reconstitution, referred to as immunoparesis, and post-transplant survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04068-5DOI Listing

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.

Leukemia 2020 May 23. Epub 2020 May 23.

Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.

The randomized, phase 3 ICARIA-MM study investigated isatuximab (Isa) with pomalidomide and dexamethasone (Pd) versus Pd in patients with relapsed/refractory multiple myeloma and ≥2 prior lines. This prespecified subgroup analysis examined efficacy in patients with renal impairment (RI; estimated glomerular filtration rate <60 mL/min/1.73 m²). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0868-zDOI Listing

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN).

Leukemia 2020 May 22. Epub 2020 May 22.

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Patients with multiple myeloma (MM) seem to be at increased risk for more severe COVID-19 infection and associated complications due to their immunocompromised state, the older age and comorbidities. The European Myeloma Network has provided an expert consensus statement in order to guide therapeutic decisions in the era of the COVID-19 pandemic. Patient education for personal hygiene and social distancing measures, along with treatment individualization, telemedicine and continuous surveillance for early diagnosis of COVID-19 are essential. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0876-zDOI Listing

Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Case Report.

Transplant Proc 2020 May 19. Epub 2020 May 19.

Bone Marrow Transplantation and Oncohematology Department, Maria Sklodowska-Curie Institute - Oncology Center, Gliwice Branch, Gliwice, Poland.

We present a case of a young patient with life-threatening pulmonary complications after allogeneic hematopoietic stem cell transplantation (HSCT). The 25-year-old woman, after HSCT for multiple myeloma, developed severe chronic graft-vs-host disease (GvHD), including bronchiolitis obliterans syndrome. During the treatment of chronic GvHD, 18 months after HSCT, she experienced sudden massive pulmonary hemorrhage with cardiac arrest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2020.01.123DOI Listing

Efficacy of ixazomib for the treatment of relapsed/refractory multiple myeloma: A protocol of systematic review and meta-analysis.

Medicine (Baltimore) 2020 May;99(20):e20211

Background: Over the past years, ixazomib has been increasingly explored for the treatment of relapsed/refractory multiple myeloma (RRMM). However, its results are still contradictory. This study will explore the efficacy and safety of ixazomib for patients with RRMM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020211DOI Listing

Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.

Medicine (Baltimore) 2020 May;99(20):e20140

Department of Neurosurgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Primary central nervous system lymphoma (PCNSL) typically shows a strong uptake of F-fludeoxyglucose (FDG) imaged by positron emission tomography (PET). Uncommonly, PCNSL demonstrates a low uptake on FDG PET. We investigated the clinicopathological characteristics of the unusual cases of PCNSL with low FDG uptake. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020140DOI Listing

Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma.

Biol Blood Marrow Transplant 2020 May 19. Epub 2020 May 19.

Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York; The Rockefeller University, New York, New York. Electronic address:

Autologous stem cell transplantation (ASCT) remains the standard-of-care for transplant-eligible multiple myeloma (MM) patients. Bortezomib with lenalidomide and dexamethasone (VRD) is the most common triplet regimen for newly diagnosed MM in the US. Carfilzomib with lenalidomide and dexamethasone (KRD) has promising efficacy and may supplant VRD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.04.011DOI Listing

The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Pharmacol Ther 2020 May 19:107579. Epub 2020 May 19.

Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy. Electronic address:

Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that sustains proteostasis network under a large variety of physiopathological conditions. Its dysregulation is often associated with the onset and progression of human diseases; hence, UPS modulation has emerged as a promising new avenue for the development of treatments of several relevant pathologies, such as cancer and neurodegeneration. The clinical interest in proteasome inhibition has considerably increased after the FDA approval in 2003 of bortezomib for relapsed/refractory multiple myeloma, which is now used in the front-line setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2020.107579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236745PMC

Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.

Blood Adv 2020 May;4(10):2236-2244

Division of Hematology, and.

Metaphase cytogenetic abnormalities, plasma cell proliferation index (PCPro), and gain 1q by fluorescence in situ hybridization (FISH) are associated with inferior survival in newly diagnosed multiple myeloma (MM) treated with novel agents; however, their role in risk stratification is unclear in the era of the revised International Staging System (R-ISS). The objective of this study was to determine if these predictors improve risk stratification in newly diagnosed MM when accounting for R-ISS and age. We studied a retrospective cohort of 483 patients with newly diagnosed MM treated with proteasome inhibitors and/or immunomodulators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001275DOI Listing

Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.

Blood Adv 2020 May;4(10):2245-2253

Cancer Outcomes, Public Policy, and Effectiveness Research Center and.

Chromosome 1 abnormalities (C1As) are common genetic aberrations among patients with multiple myeloma (MM). We aimed to evaluate the significance of C1As among a contemporary cohort of patients with MM in the United States. We used electronic health records from the Flatiron Health database to select patients newly diagnosed with MM from January 2011 to March 2018 who were tested using fluorescence in situ hybridization within 90 days of diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001425DOI Listing

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.

J Clin Oncol 2020 May 22:JCO2000437. Epub 2020 May 22.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Purpose: Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.00437DOI Listing

Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment.

Br J Haematol 2020 May 22. Epub 2020 May 22.

Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA.

Serum B-cell maturation antigen (sBCMA) is a novel biomarker for B-cell malignancies. A normal reference range (<82·59 ng/ml) has been recently established but the impact of achieving normal levels to outcomes for patients receiving treatment for B-cell malignancies has not been studied. We first found that among multiple myeloma (MM) patients starting a new treatment, those who begin treatment within normal sBCMA limits (<82·59 ng/ml) have improved progression-free survival (PFS; P = 0·0398) and overall survival (OS; P = 0·0217) than those who do not. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16752DOI Listing

Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide.

Clin Interv Aging 2020 4;15:619-633. Epub 2020 May 4.

Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.

Multiple myeloma is a hematologic malignancy that predominantly affects older adults, with a median age at diagnosis of 70 years old. A mainstay of multiple myeloma treatment is lenalidomide, which is an immunomodulatory drug (IMiD) that changed the treatment paradigm for multiple myeloma. This is particularly true for older adults who do not undergo autologous stem cell transplantation (ASCT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CIA.S196087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210019PMC

No Differences in Outcomes Between JAK2 V617F-Positive Patients with Variant Allele Fraction < 2% Versus 2-10%: A 6-Year Province-wide Retrospective Analysis.

Clin Lymphoma Myeloma Leuk 2020 Apr 21. Epub 2020 Apr 21.

Michael Smith Genome Sciences Centre, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Introduction: JAK2 V617F mutation is one of the major criteria in the diagnosis of myeloproliferative neoplasms (MPN) and its variant allele fraction (VAF) determines the disease phenotype and outcomes. This study aimed to define characteristics and outcomes of patients with JAK2 V617F VAF < 2% compared to patients with VAF 2%-10%.

Patients And Methods: We included 5079 patients with JAK2 V617F tested during 2010-2015 and identified 216 patients (4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.04.010DOI Listing

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapy.

Br J Haematol 2020 May 21. Epub 2020 May 21.

Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.

Infection with the novel coronavirus SARS-CoV-2 virus resulting in an acute respiratory disease (COVID-19 disease) is the cause of the current pneumonia pandemic, with a rapid rise in cases being reported in the European Union and UK (1, 2). The UK index case was identified on the 31 of January, 2020 and given the rapid spread and high mortality rate of COVID-19, it is imperative to define the impact on patients with co-existing medical conditions(3). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16874DOI Listing

Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials.

Blood 2020 May 21. Epub 2020 May 21.

Freeman Hospital, University of Newcastle, Leeds, United Kingdom.

Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs (IMiDs) are at high venous thrombosis (VTE) risk, but data are lacking from large prospective cohorts. We present thrombosis outcome data from Myeloma IX (n=1936) and Myeloma XI (n=4358), phase III randomized controlled trials for NDMM, treating transplant-eligible and ineligible patients before and after publication of thrombosis prevention guidelines. In Myeloma IX, compared to CTD (cyclophosphamide, thalidomide and dexamethasone), transplant-eligible patients randomized to CVAD induction (cyclophosphamide, vincristine, doxorubicin and dexamethasone) had higher VTE risk (22. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005125DOI Listing

Promotion of cell membrane fusion by cell-cell attachment through cell surface modification with functional peptide-PEG-lipids.

Biomaterials 2020 May 11;253:120113. Epub 2020 May 11.

Department of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan; Department of Immunology, Genetics and Pathology (IGP), Uppsala University, Dag Hammarskjölds Väg 20, SE-751 85, Uppsala, Sweden. Electronic address:

Cell fusion is a fundamental event in various biological processes and has been applied to a number of biotechnologies. However, cell fusion efficiency is still low and strongly depends on cell lines and skills, though some improvements have been made. Our hypothesis is that two distinct cell membranes need to be brought together for cell membrane fusion, which is important for mimicking cell fusion in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2020.120113DOI Listing

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma.

Front Oncol 2020 6;10:676. Epub 2020 May 6.

Service d'Hématologie et Thérapie cellulaire, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.

As the global population is aging and survival in multiple myeloma (MM) is increasing, treating older MM patients, redefined as non-transplant eligible (NTE), is becoming more frequent. Yet, treating these patients remains a real challenge especially because of a marked heterogeneity in the population and an increased susceptibility to treatment toxicity. Indeed, the balance between efficacy and safety must be considered at all time throughout the treatment history for these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218111PMC

Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma.

Biomark Res 2020 13;8:14. Epub 2020 May 13.

1Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, NO, 3663 North Zhongshan Road, Shanghai, 200065 China.

Background: Treatment with chimeric antigen receptor (CAR)-engineered T cells directed against the B-cell maturation antigen (BCMA) promoted transient recovery from multiple myeloma (MM). However, the absence of this antigen on immature plasma cells may limit the efficacy of this modality and facilitate relapse. The purpose of this study is to characterize a novel CAR that includes both a single-chain variable fragment (scFv)-BCMA and an scFv-CD19 in tandem orientation (tan-CAR) in an attempt to target both BCMA and CD19 expression on MM cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00192-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222432PMC

Primary extramedullary plasmacytoma of the eyelid conjunctiva - A case report and review of the literature.

Ann Med Surg (Lond) 2020 Jul 7;55:1-4. Epub 2020 May 7.

Ophthalmology Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Extramedullary plasmacytomas (EMPs) are uncommon plasma cell tumors that develop in soft tissue as isolated tumors without osseous involvement while secondary lesions are associated with systemic multiple myeloma (MM). Primary extramedullary lesions are most commonly found in upper respiratory tract, gastrointestinal tract and lymph nodes. They can be found either in patients with history of MM or preceding the manifestation of a systemic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amsu.2020.04.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229271PMC

Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.

Br J Cancer 2020 May 21. Epub 2020 May 21.

Cancer Institute, University College London, London, UK.

Background: Exercise may improve fatigue in multiple myeloma survivors, but trial evidence is limited, and exercise may be perceived as risky in this older patient group with osteolytic bone destruction.

Methods: In this Phase 2 Zelen trial, multiple myeloma survivors who had completed treatment at least 6 weeks ago, or were on maintenance only, were enrolled in a cohort study and randomly assigned to usual care or a 6-month exercise programme of tailored aerobic and resistance training. Outcome assessors and usual care participants were masked. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0866-yDOI Listing

Rising to the challenge: designing, implementing and reporting exercise oncology trials in understudied populations.

Br J Cancer 2020 May 21. Epub 2020 May 21.

Department of Biomedical Engineering, University of Alberta, Edmonton, AB, Canada.

Exercise can improve cancer-related fatigue, quality of life and physical fitness, but is understudied in less common cancers such as multiple myeloma. Studying less common cancers and the adoption of novel study designs and open-science practices would improve the generalisability, transparency, rigour, credibility and reproducibility of exercise oncology research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0868-9DOI Listing

New drugs in early development for treating multiple myeloma: all that glitters is not gold.

Expert Opin Investig Drugs 2020 May 20. Epub 2020 May 20.

Myeloma Unit, Division of Hematology, University of Torino Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino ,, Torino, Italy.

Introduction: . The last twenty years have introduced new therapeutic agents for multiple myeloma (MM); these include proteasome Inhibitors (PIs), immunomodulatory drugs (IMDs) and monoclonal antibodies (mAbs). However, MM remains incurable, hence there is an unmet need for new agents for the treatment of advanced refractory disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2020.1772753DOI Listing

Structural and Functional Analyses of the FAM46C/Plk4 Complex.

Structure 2020 May 12. Epub 2020 May 12.

Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address:

FAM46C, a non-canonical poly(A) polymerase, is frequently mutated in multiple myeloma. Loss of function of FAM46C promotes cell survival of multiple myeloma, suggesting a tumor-suppressive role. FAM46C is also essential for fastening sperm head and flagellum, indispensable for male fertility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.str.2020.04.023DOI Listing

Search for multiple myeloma risk factors using Mendelian randomization.

Blood Adv 2020 May;4(10):2172-2179

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.

The etiology of multiple myeloma (MM) is poorly understood. Summary data from genome-wide association studies (GWASs) of multiple phenotypes can be exploited in a Mendelian randomization (MR) phenome-wide association study (PheWAS) to search for factors influencing MM risk. We performed an MR-PheWAS analyzing 249 phenotypes, proxied by 10 225 genetic variants, and summary genetic data from a GWAS of 7717 MM cases and 29 304 controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2020001502DOI Listing

Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.

Blood Adv 2020 May;4(10):2163-2171

Department of Hematology, Hospital Universitario 12 de Octubre (H12O), Universidad Complutense de Madrid, Madrid, Spain.

Lenalidomide is an immunomodulatory drug approved for maintenance treatment in newly diagnosed multiple myeloma, and it has been shown to improve progression-free survival (PFS) and, in several studies, overall survival. Nevertheless, the impact of prolonged treatment with lenalidomide on the kinetics of minimal residual disease (MRD) and its prognostic impact have not been studied in depth. To obtain better knowledge in this regard, we retrospectively analyzed 139 patients who received lenalidomide maintenance in real-world clinical practice and whose MRD levels were observed during the treatment period by multiparametric flow cytometry or next-generation sequencing with a sensitivity of at least 10-4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2020001508DOI Listing

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities.

Front Oncol 2020 5;10:636. Epub 2020 May 5.

Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.

Immunotherapy has recently emerged as a promising treatment option for multiple myeloma (MM) patients. Profound immune dysfunction and evasion of immune surveillance are known to characterize MM evolution and disease progression. Along with genomic changes observed in malignant plasma cells, the bone marrow (BM) milieu creates a protective environment sustained by the complex interaction of BM stromal cells (BMSCs) and malignant cells that using bidirectional connections and cytokines released stimulate disease progression, drug resistance and enable immune escape. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214816PMC

Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1 Myeloma Cells and Release Type-1 Cytokines.

Front Oncol 2020 5;10:544. Epub 2020 May 5.

Division of Hematology and Oncology, Bone Marrow Transplantation and Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, United States.

Multiple myeloma (MM) remains incurable despite advances in chemotherapy, targeted therapies, and immunotherapy. Bispecific antibody (BiAb)-armed activated T cells (BATs) have been developed for targeting and treatment of solid and hematologic malignancies. BATs are serial killers of tumor cells, secrete Th cytokines, and induce adaptive cellular and humoral immune responses in patients (pts). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00544DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214537PMC

Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans.

Front Immunol 2020 5;11:774. Epub 2020 May 5.

Department of Biomedicine, Faculty of Health, Aarhus University, Aarhus, Denmark.

We aimed at establishing a sensitive and robust assay for estimation of systemic complement activation at complement component C3 level in mouse and human plasma samples. In order to capture the activation products iC3b and C3dg in a specific and physiological relevant manner we utilized a construct consisting of the iC3b/C3dg-binding site of human complement receptor 2 (CR2) attached to an Fc-part of mouse IgG. This construct binds C3dg and iC3b from both mice and humans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.00774DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214740PMC

Hematological malignancies in Ukraine in post-Chernobyl era: sources of data and their preliminary analysis.

Ann Hematol 2020 May 19. Epub 2020 May 19.

SI "Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine", Lviv, Ukraine.

The major sources of the data on the hematological malignancies in the post-Chernobyl period in the regions of Ukraine differing by the levels of the residual contamination with radionuclides have been analyzed. According to the data collected from the primary hematological facilities in Ukraine in 2010-2017, the incidence of lymphoid neoplasms from mature B cells, acute myeloid leukemia, and multiple myeloma in the most contaminated regions was higher than in the less contaminated ones. For the first time, the relative contribution of the several specific types of leukemia in the total diagnosed hematological malignancies has been analyzed throughout 1997-2017 based on the in-house database compiled by the Reference Laboratory of RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, the National Academy of Sciences of Ukraine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04076-5DOI Listing

A systematic review and meta-analysis of haematological malignancies in residents living near petrochemical facilities.

Environ Health 2020 May 19;19(1):53. Epub 2020 May 19.

Department of Sociology, University of Warwick, Coventry, CV4 7AL, UK.

Background: The petrochemical industry is a major source of hazardous and toxic air pollutants that are recognised to have mutagenic and carcinogenic properties. A wealth of occupational epidemiology literature exists around the petrochemical industry, with adverse haematological effects identified in employees exposed to 'low' concentrations of aromatic hydrocarbons (benzene, toluene, ethylbenzene, and xylene). Releases from the petrochemical industry are also thought to increase the risk of cancer incidence in fenceline communities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12940-020-00582-1DOI Listing

Hematological Diseases and Osteoporosis.

Int J Mol Sci 2020 May 16;21(10). Epub 2020 May 16.

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.

Secondary osteoporosis is a common clinical problem faced by bone specialists, with a higher frequency in men than in women. One of several causes of secondary osteoporosis is hematological disease. There are numerous hematological diseases that can have a deleterious impact on bone health. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21103538DOI Listing

Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1.

Cancers (Basel) 2020 May 15;12(5). Epub 2020 May 15.

Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Inserm, Université de Nantes, Université d'Angers, 44000 Nantes, France.

Chronic stimulation by infectious or self-antigens initiates subsets of monoclonal gammopathies of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or multiple myeloma (MM). Recently, glucosylsphingosine (GlcSph) was reported to be the target of one third of monoclonal immunoglobulins (Igs). In this study of 233 patients (137 MGUS, 6 SMM, 90 MM), we analyzed the GlcSph-reactivity of monoclonal Igs and non-clonal Igs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051254DOI Listing

Storage, Utilization and Disposal of Hematopoietic Stem Cell Products in Multiple Myeloma Patients.

Biol Blood Marrow Transplant 2020 May 16. Epub 2020 May 16.

Department of Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany.

High-dose chemotherapy (HD-CHT) and autologous blood stem-cell transplantation (ABSCT) represent the standard of care in multiple myeloma (MM) for transplant-eligible patients. Up to three HD-CHT/ABSCT treatments may be administered during the course of disease, including during late-onset relapse. Transplant centers routinely collect more than one peripheral blood stem cell (PBSC) graft. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.04.030DOI Listing

Covid-19 and Myeloma: what are the implications for now and in the future?

Br J Haematol 2020 May 19. Epub 2020 May 19.

Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute, City of Hope Cancer Center, USA.

The pandemic has affected every aspect of myeloma care. Immediate focus is minimizing risk of contracting COVID-19 and the sequelae of infection. However, what does the future hold for our patients? What lessons will be taken forward to tackle myeloma in the fiscally constrained future? If we embrace the challenges that will emerge in the post-pandemic environment, the treatment delivered to patients could be more cost effective and better tailored than before. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16815DOI Listing

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.

JCI Insight 2020 May 19. Epub 2020 May 19.

Department of Hematology/Oncology, Emory University School Of Medicine, Atlanta, United States of America.

Introduction: PD-1 and PD-L1 have been studied interchangeably in the clinic as checkpoints to reinvigorate T cells in diverse tumor types. Data for biologic effects of checkpoint blockade in human premalignancy are limited.

Methods: We analyzed the immunologic effects of PD-L1 blockade in a clinical trial of atezolizumab in patients with asymptomatic multiple myeloma (AMM), a precursor to clinical malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.129353DOI Listing

Biclonal myeloma in renal failure.

Cent Eur J Immunol 2020 ;45(1):122-124

University Hospital Alexandrovska, Sofia, Bulgaria.

Multiple myeloma is a clonal proliferation of the plasma cell line that accounts for approximately 10% of all hematological malignancies. It is characterized by abnormal growth of plasma cells producing monoclonal immunoglobulin or light chain (paraprotein), with subsequent development of osteolytic bone lesions, anemia, hypercalcemia, and renal failure. In 3-6% of myeloma patients, more than one monoclonal protein (usually two) is discovered, with different heavy or light chain or both. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/ceji.2020.94714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226549PMC
January 2020

The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies - A Narrative Review.

Cancer Manag Res 2020 29;12:2961-2977. Epub 2020 Apr 29.

Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.

Despite the presence of many hematological prognostic indexes, clinical course and overall survival are often highly variable even within the same patient subgroup. Recent studies suggest that simple, cost-effective, low-risk tests such as neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ratio (LMR) may be used to evaluate the prognosis. Their role has been well confirmed in diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL) and multiple myeloma (MM), but until now the prognostic significance of NLR and LMR in leukemias has not been widely reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S245928DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196794PMC

The Synchronous Presence of Multiple Myelomas and Other Primary Malignant Tumors: Case Series with Literature Review.

Cancer Manag Res 2020 24;12:2829-2838. Epub 2020 Apr 24.

Henan Institute of Haematology, Department of Hematology, Henan Cancer Hospital, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, People's Republic of China.

Objective: The synchronous presence of multiple myeloma (MM) and other primary malignant tumors (PMTs) were rarely reported. This study aimed to analyze several cases of MM and other PMTs in order to improve clinicians' understanding of multiple myeloma (MM) with sMPMTs.

Methods: This study was a retrospective trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S238288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187932PMC